What's new?

Capital raise enables Sofinnova MD Start’s pioneering team to further support clinicians in transforming innovative ideas into medical realities Paris – July 13, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the final close of its ...

• Financing co-led by Novo Holdings, Sofinnova Partners, Droia Ventures and LSP Dementia Fund, with participation from Polaris Partners, Polaris Innovation Fund, Sanofi Ventures, V-Bio Ventures and VIB • Developing small molecules to repair neuronal dysfunction and resolve neuroinflammation • Innovative drug discov...

- Financing will be used to further develop proprietary discovery platform and progress pipeline targeting disease control and weed suppression - Company well positioned to enter and transform the EUR 47 billion-plus market for pesticides, initially targeting $28 billion herbicides and fungicides markets in America...

Ghent, BELGIUM – 01 July 2021 – Biotalys NV (“Biotalys” or the “Company”) an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for a more sustainable and safer food supply, today announces the results of its initial public offering of n...

Key investments made through the Sofinnova Telethon Fund underscore the venture capital firm’s commitment to fostering a thriving Italian biotech ecosystem AAVantgarde Bio, Alia Therapeutics, and Borea Therapeutics are developing promising new therapies for rare, genetic disorders Milan, Italy – June 30, 2021 - Sof...

Financing led by Casdin Capital, Sofinnova Partners - initial seed investor, and an undisclosed investor Mnemo delivers epigenetic antigens, stronger T cells and best-in-class manufacturing established with groundbreaking research from Institut Curie and Memorial Sloan Kettering Paris, France, June 16, 2021 – Mnemo...

STOCKHOLM, 15 June 2021 – EnginZyme, enabling the future of sustainable chemical production, announces that the World Economic Forum has selected it as one of the 2021 Technology Pioneers. This prestigious recognition highlights the company’s innovations that address the challenges of the chemical industry in the 2...

PARIS, France – June 8, 2021 - Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today that its medtech accelerator, Sofinnova MD Start III, is launching a call for early-stage projects. Sofinnova MD Start III is part of the Sofinnova platform of f...

Paris, France, May 25, 2021, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the highly...

PARIS, France, May 24, 2021 – 6:30 pm (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, announces positive phase 2b clinical induction and p...